Exelixis Inc.'s data for its tyrosine kinase inhibitor cabozantinib in the Phase III CELESTIAL study of second-line-plus advanced hepatocellular cancer are positive, but raised some concerns about competitive prospects, particularly against Bristol-Myers Squibb Co.'s approved PD-1 inhibitor Opdivo and Merck & Co. Inc.'s Keytruda, which is also now poised for approval in this tumor type.
Exelixis' CELESTIAL Liver Trial Succeeds, But Can Cabozantinib Compete?
CELESTIAL second-line liver cancer study is positive, but 4% response rate pales in comparison to PD-1 performance of Bristol's Opdivo and Merck's Keytruda.
